Additionally, a biological agent—chosen based on tumor-specific and patient-specific criteria—may be included, which can be either anti-vascular endothelial growth factor (VEGF) (e.g., bevacizumab, aflibercept, or ramucirumab) or anti-epithelial growth factor receptor (EGFR) antibodies (such as panitumumab and cetuximab) [3–5]. This evidence concerns the gene VEGFA and neoplasm.